5th Annual Traumatic Brain Injury Conference
April 15-16, 2015 Washington, DC
Now in its 5th year, Arrowhead's Annual Traumatic Brain Injury Conference brings together researchers and clinicians from industry, academia, the military and government to present ground-breaking research in a variety of areas related to traumatic brain injury.
• Current Clinical Management of TBI
• Large-scale Observational Studies of TBI
• Advances and Opportunities for TBI Biomarkers
• Neuroimaging Research and Practice
• Biomarkers for Monitoring Response to TBI Treatments
• Learning From Other CNS disorders/Diseases
• TBI Clinical and Preclinical Trials and Models
• Emerging Tools for Diagnosis and Assessment of Brain Injuries
• Outcomes Research
This event provides a special opportunity for a variety of stakeholders to present original research and analysis aimed at providing a full picture of the progress being made towards better diagnosis, treatment and long-term care for TBI survivors. At this annual event, physicians, nurses, neurosurgeons, scientists, and drug/diagnostic developers from all over the world network and learn from one another.
The 2015 Conference
Following up on 2014’s successful conference and record-breaking attendance, the 2015 event will bring together the world’s leading TBI researchers and thought leaders to discuss the following:
• Clinical case studies to showcase gaps in treatment and discuss possible solutions
• Advances in neuroimaging (PET imaging, volumetric MRI, etc.)
• Lessons learned from failed TBI clinical trials
• Giving voice to the patient community
• TBI and CTE outcomes research
• TBI-related dementia and neurodegenerative diseases
• Use of biomarkers as surrogate outcome measures in TBI trials
• Biomarkers in diagnosis and drug development in TBI
• TBI international initiatives and natural history studies
• Challenges and solutions in the diagnosis of sport-related concussions
• Review of TBI pharmacology and product candidates in the pipeline
Key Questions Answered
• How can animal model results translate to clinical research?
• What are the key patient populations for future clinical trials?
• What outcomes should new clinical trials measure?
• How can companion diagnostics and biomarkers improve therapeutic interventions and outcome prediction?
• What are the regulatory barriers facing developers of both companion diagnostics and new therapies?